BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired shares from pre-IPO venture capital shareholders Dienstag, 19. Juli 2016 - 07:00
MEDIA RELEASE
BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired shares from pre-IPO venture capital shareholders
Zurich-Schlieren, July 19, 2016. Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPins, was informed by Biotechnology Value Fund, L.P. and other entities affiliated with BVF Partners L.P. (BVF), a San Francisco-based investor focused on biotechnology, that it holds 4.58% of the voting rights and share capital of Molecular Partners. According to BVF’s declaration dated July 18, 2016 pursuant to Article 120 of the Swiss Financial Market Infrastructure Act, the 3% threshold was crossed on July 18, 2016.
On July 18, 2016, Molecular Partners was also informed that Index Ventures and Essex Woodlands Health Ventures have fallen below the 15% threshold on the same day.
None of the founders or members of the management team sold any shares in this context. Christian Zahnd, CEO of Molecular Partners commented: “We are very happy to see that we could gain more interest and support from BVF. We have extensive experience in working together with BVF; their skills and understanding of the long-term value perspective of Molecular Partners makes it a privilege to work with such a highly reputable group.”
Molecular Partners welcome this important step to further expand its long-term oriented specialist investor base.
Financial Calendar 2016
Publication of Half-year Results 2016 | September 1, 2016 |
Publication of Quarterly Management Statement Q3 2016 | October 27, 2016 |
http://investors.molecularpartners.com/financial-calendar-and-events/
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.
For further details, please contact:
Dr. Christian Zahnd, CEO
christian.zahnd@molecularpartners.com
Tel: +41 (0) 44 755 77 00
Andreas Emmenegger, CFO
andreas.emmenegger@molecularpartners.com
Tel: +41 (0) 44 755 77 00
Rolf Schläpfer
Hirzel.Neef.Schmid.Counselors
rolf.schlaepfer@konsulenten.ch
Tel: +41 (0) 43 344 42 42
